The funding will also support the company in conducting a first-in-man dose ranging study to evaluate the anthrax vaccine.
Vaxin president and CEO Bill Enright said this is a great opportunity for Vaxin to apply their vaccine development experience to a critical need and they thank the team at BARDA for this contract to advance this potentially important new technology.